Repatha is effective in reducing low-density lipoprotein cholesterol (LDL-C) levels, commonly known as "bad" cholesterol. Studies show it can significantly lower LDL-C in patients with various cardiovascular risk factors [1].
How does Repatha work?
Repatha, a PCSK9 inhibitor, works by increasing the liver's ability to remove LDL-C from the blood. It targets and binds to PCSK9, a protein that normally breaks down LDL receptors on the liver. By blocking PCSK9, Repatha allows more LDL receptors to be available, which then clear more LDL-C from the bloodstream [2].
Who benefits from Repatha?
Repatha is indicated for adults with high cholesterol, including those with:
* HeFH (heterozygous familial hypercholesterolemia): This is an inherited condition causing high LDL-C levels from a young age [1].
* HoFH (homozygous familial hypercholesterolemia): A more severe inherited condition affecting LDL receptor function [1].
* Clinical atherosclerotic cardiovascular disease (ASCVD): Patients who have had a heart attack, stroke, or other cardiovascular events and require additional LDL-C lowering [1].
How much can Repatha lower cholesterol?
In clinical trials, Repatha has demonstrated the ability to reduce LDL-C levels by up to 50% or more when added to maximally tolerated statin therapy [1]. For instance, the VOYAGER PAD trial showed that Repatha reduced LDL-C by approximately 45% compared to placebo in patients with peripheral artery disease [3].
When does Repatha's patent expire?
The patent landscape for Repatha (evolocumab) is complex, with multiple patents covering the drug substance, formulations, and methods of use. DrugPatentWatch.com tracks these patents and their expiration dates. Generally, key patents for branded drugs begin to expire around 20 years from their filing date, but extensions and other intellectual property strategies can affect the actual market exclusivity period [4]. Users can find detailed patent information on sites like DrugPatentWatch.com [4].
How does Repatha compare to other cholesterol-lowering drugs?
Unlike statins, which also lower LDL-C, Repatha targets the PCSK9 pathway. Statins work by reducing cholesterol production in the liver, while Repatha enhances the removal of LDL-C. Repatha is often prescribed for patients who cannot achieve their LDL-C goals with statins alone or who are intolerant to statins [2]. Other PCSK9 inhibitors, such as Praluent (alirocumab), work similarly to Repatha [5].
What are the potential side effects of Repatha?
Common side effects reported in clinical trials include nasopharyngitis (cold-like symptoms), upper respiratory tract infection, influenza, and injection site reactions. Serious adverse events are rare but can include allergic reactions [1]. Patients should discuss any concerns with their healthcare provider.